Drug profile · INN
difamilast
MOIZERTO
difamilast (MOIZERTO) is a phosphodiesterase 4 inhibitor. Route of administration: topical. Current US regulatory status: approved.
Drug details — difamilast
- US status
- approved
- Class
- —
- Route
- TOPICAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
difamilast (MOIZERTO) is a phosphodiesterase 4 inhibitor. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
Phosphodiesterase 4 inhibitor
Primary target: Phosphodiesterase 4
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| PMDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is difamilast?
difamilast (MOIZERTO) is a phosphodiesterase 4 inhibitor. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for difamilast?
MOIZERTO is a marketed brand name for difamilast. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of difamilast?
difamilast has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.